A new clinical trial is set to compare the efficacy of Endoscopic Ultrasound Fine Needle Biopsy (EUS-FNB) against Endoscopic Ultrasound Core Needle Biopsy (EUS-CNB) in diagnosing pancreatic lesions. Sponsored by the University of California, Davis, this trial could redefine approaches for diagnosing pancreaticobiliary disorders.
Published: November 23, 2025
What is this trial?
The trial aims to evaluate two methods of endoscopic ultrasound-guided biopsy for pancreatic lesions. Specifically, it will compare the precision and diagnostic reliability of Fine Needle Biopsy (FNB) devices and Core Needle Biopsy (CNB) devices.
Pancreatic lesions can be challenging to diagnose due to their biological complexity. Clinicians hope this study will provide clarity on whether modern CNB techniques offer meaningful advantages over the widely adopted method of FNB.
The trial is currently listed as not yet recruiting on ClinicalTrials.gov, making this period an essential time for potential participants to learn more about their eligibility.
The diagnostic focus
Conditions Studied:
- Pancreaticobiliary disorders
- Biopsy-based tissue sampling
- EUS-guided approaches
EUS-guided biopsies allow physicians to obtain high-quality tissue samples under ultrasound imaging, which minimizes the risk of invasive diagnostic complications. Among EUS-based biopsy techniques, FNB has gained widespread adoption due to its reliability in extracting cellular material efficiently.
What sets Core Needle Biopsy apart?
CNB provides practitioners with a larger tissue sample than its FNB counterpart, potentially allowing histological evaluation to complement cytology. The trial will determine whether this additional tissue volume positively impacts diagnostic yield and clinical decision-making.
Frequently Asked Questions
-
Who sponsors this trial?
The University of California, Davis, is responsible for planning and sponsorship.
-
Are participants being recruited?
According to ClinicalTrials.gov, this trial is not yet recruiting. Check the listed announcement for updates.
-
Why focus on pancreatic lesions?
Pancreatic lesions are often difficult to diagnose due to their subtle imaging and biological patterns.
Implications for professionals
This trial highlights the continuing evolution in medical device applications for biopsy and precision diagnostics. For clinicians, understanding the potential strengths and limitations of FNB versus CNB enables improved clinical pathways and patient outcomes.
Regulatory professionals should also note progress in comparative device efficacy data, which could influence future technologies entering the U.S. and global markets.
Disclaimer
This article is for informational purposes only and does not constitute legal, medical, or regulatory advice. Always consult organizational guidelines or legal counsel for specific compliance requirements.
Announcement details
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07240818?term=medical+device